July 12, 2016

Education & Outreach

  • The Michigan Alzheimer’s Disease Center is committed to improving knowledge and awareness of dementia through collaborative education and outreach efforts. To support this commitment, we have established partnerships with several University of Michigan departments and institutions, and with community organizations, such as the Alzheimer’s Association. Our partnerships enable us to provide, co-sponsor, support and promote educational programs for individuals experiencing memory loss and for care partners. Please check out our events calendar for a listing of educational and support programs offered by the Center, U-M Geriatrics Center, U-M Silver Club programs, and the Alzheimer’s Association.

  • Speakers’ Bureau

    Our Center sponsors a Speakers Bureau made up of our physicians, neuropsychologists, public health educators and clinical social workers that specialize in aging and dementia.

    The Speakers Bureau offers educational opportunities to University of Michigan students and professionals and to community organizations, and agencies and institutions across Michigan and Ohio.

    Presentation topics vary widely and can be tailored to the interests and needs of the audience.  Please check out our speakers and topics in the menu below. To bring a speaker to your organization, please contact the MADC Outreach Coordinator at (734)-615-5319.

    Andrew Leiberman, MD PhD

    Dr. Andrew Lieberman is the Gerald D. Abrams Professor in the Department of Pathology and Director of Neuropathology at the University of Michigan. Dr. Lieberman received his BS from Duke University and his MD, PhD from the University of Maryland Medical School. He completed residency training in Anatomic Pathology and fellowship training in Neuropathology at the University of Pennsylvania. He trained as a research fellow with Dr. Kenneth Fischbeck at the Neurogenetics Branch NINDS, NIH, and then joined the University of Michigan Medical School faculty in 2001. Dr. Lieberman’s research has focused on the mechanism of neurodegeneration in inherited neurological disorders. His laboratory uses cell culture and mouse models to explore the pathogenesis of Kennedy’s disease, a polyglutamine expansion disorder, and Niemann-Pick C, a lysosomal storage disease resulting from impaired lipid trafficking.

    Bruno Giordani, PhD

    Dr. Giordani is a Chief of Psychology, and a tenured Professor in the Psychiatry, Neurology, and Psychology Departments as well as the School of Nursing. He is a University Faculty Ombuds at the University of Michigan. Associated with the MADC for over 25 years, Dr. Giordani has a longstanding history of connecting with the community to promote a better understanding of Alzheimer’s disease and related conditions. He has served on the Executive Board of the Alzheimer’s Association, Michigan Great Lakes Chapter (MGLC) since 2007 and has been both its Board Chair and National Representative, as well as a Steering Committee being a member of the national Association’s Assembly Steering Committee. His research initiatives focus on a cross-cultural perspective on the early assessment of cognitive and behavioral changes associated with medical illness and the interaction of cognition and mobility across the life-span. Dr. Giordani completed his MA and PhD in Clinical Psychology at the University of Virginia and received his postdoctoral training in Clinical and Research Neuropsychology at the University of Michigan.

    Edna Rose, PhD, MSW, RN-BC

    Since 2008, Dr. Rose has assisted the MADC with connecting to minority communities to provide education about the risk factors associated with dementia and the benefits of participating in research. She has successfully enhanced minority inclusion in our MADC supported studies through linkages at local churches, sororities and other social organizations. Dr. Rose received her MSW and PhD from Clark Atlanta University in Social Work Planning and Administration, and her undergraduate nursing degree from Kennesaw University in Atlanta, GA.

    Stephen Campbell, LLMSW

    Stephen aids in the process of helping potential volunteers find a study best suited to their needs and interests. He is most interested in providing ongoing support to research volunteers to help them locate resources in a timely and efficient manner. He earned his Master’s degree in Social Work and Graduate Certificate in Gerontology at Eastern Michigan University.

    Laura Rice-Oeschger, LMSW

    Since 2012, Laura has lead the Wellness Initiative for the MADC where she designs, implements and evaluates well-being and mindfulness-based programming for caregivers and adults living with dementia. Moved by family experiences with long-term illness and memory loss, Laura has worked in dementia care since 1994 in a variety of capacities. She was the first Director of the University of Michigan Geriatrics Center Silver Club Memory Loss Programs prior to serving as clinical manager of the Early Stage Initiative for the Los Angeles regional Alzheimer’s Association. She is a national and state presenter on memory loss and caregiver well-being and holds advanced professional certifications in aging, dementia and contemplative clinical care. Laura received her MSW from the University of Michigan School of Social Work.

    Henry Paulson, MD, PhD

    Dr. Paulson directs the MADC, working closely with MADC staff to define and implement the diverse initiatives through which the center fulfills its three-part mission. He joined the Center as Associate Director in 2009 and assumed Directorship in 2011. He has worked for more than twenty years on degenerative brain diseases, both inherited and acquired. As a neurologist and neuroscientist, Dr. Paulson is deeply committed to translating findings from the research bench to the patient bedside. Toward that goal, he is focused on building connections between scientists, clinicians and the public, not only across the University of Michigan campus but also across the state of Michigan. He received his MD and PhD degrees from Yale University School of Medicine and his Neurology training at the University of Pennsylvania.

    Nancy Barbas, MD, MSW

    Associated with the MADC for many years, Dr. Barbas is Associate Professor of Neurology and Director of the Cognitive Disorders Clinic at the University of Michigan Health System. She has been on the faculty of University of Michigan Medical School and Health System since 1991. Dr. Barbas’s clinical interests include cognitive disorders in adults, such as Alzheimer’s disease and related dementias, and general geriatric neurology. She is active in clinical trial research for treatment development for Alzheimer’s disease and other dementias. She actively trains the next generation of professionals, teaching them state-of-art dementia care techniques and research skills. She has published articles and chapters on dementia topics. Nan has spent the majority of her years in higher education in Ann Arbor, Michigan obtaining Bachelors of Arts (BA), Masters in Social Work (MSW), and Doctor of Medicine (M.D.) degrees from the University of Michigan. She continued her training at Tufts New England Medical Center in Boston completing a Neurology Residency and a Neuro-ophthalmology Fellowship.

    Sami Barmada, MD, PhD

    Dr. Barmada currently serves as Associate Professor of Neurology at the University of Michigan. He was recruited from UCSF to the University of Michigan in 2013. Dr. Barmada divides his time between the laboratory, Cognitive Disorders Program, and the classroom. In his investigations of molecular mechanisms in FTD including TDP43 proteinopathies, Dr. Barmada employs automated microscopy. He treats patients in the Cognitive Disorders Program, with an emphasis on individuals with dementia and motor neuron disease. Dr. Barmada is also an Assistant Professor of Neurology.

    Benjamin Hampstead, PhD, ABPP/CN

    Dr. Hampstead joined the U-M faculty in September 2014 as an Associate Professor in Psychiatry and Staff Neuropsychologist in the Ann Arbor VA Healthcare System. He is the Clinical Core Leader at the MADC. Dr. Hampstead is an expert in functional imaging and nonpharmacological approaches to enhance age-related memory function (e.g., cognitive rehabilitation and direct brain stimulation). Through his appointment in the Ann Arbor VA Healthcare System, he is well-positioned to ensure that our older veterans have access to cutting-edge research and clinical procedures.

    Scott Roberts, PhD

    Dr. Roberts' research interests focus on the process and impact of genetic risk assessment for adult-onset disorders. He has served since 2001 as Co-Principal Investigator of the REVEAL Study (Risk Evaluation & Education for Alzheimer's Disease), an NIH-funded series of clinical trials assessing the psychological and behavioral impact of genetic risk disclosure for Alzheimer's disease (AD). Now having recently completed its fourth trial, the REVEAL Study has examined the effects of APOE genotype-based risk disclosure to individuals at elevated risk for AD. In addition, Dr. Roberts is joint PI of a NIH-funded project to examine the motivations, attitudes and behaviors of consumers receiving personal genomics services. Finally, Dr. Roberts collaborates with investigators at the U-M Comprehensive Cancer Center on a project to examine ethical and health communication issues involved in the use of whole-genome sequencing to customize care of patients with advanced and refractory cancers. This project is part of the national NIH Clinical Sequencing Exploratory Research (CSER) consortium.

    Peter Lichtenberg, PhD, ABPP

    Peter A. Lichtenberg, Ph.D., ABPP is the Director of The Institute of Gerontology and the Merrill Palmer Skillman Institute and Professor of Psychology at Wayne State University in Detroit He is particularly interested in the area of intersection between financial capacity and financial exploitation; finding ways to balance autonomy and protection for older adults. In 2013 he published the first nationally representative study on predictors of older adult scam victims. He recently completed the creation of the Lichtenberg Financial Decision Making Rating Scale, and the Lichtenberg Financial Decision Screening Scale: He has authored 7 books and over 200 scientific articles and book chapters in Geropsychology including being the senior editor for the American Psychological Association’s Handbook of Clinical Geropsychology

    Deborah Levine, MD, MPH

    Deborah LevineDr. Levine’s research aims to improve the lives and care of adults with chronic disease. Her primary research interests are the epidemiology, prevention, and care of stroke and cognitive impairment, with a focus on vascular risk factors, adherence, and health disparities. Her research includes improving the quality of stroke care; stroke-related dementia and cognitive impairment; and reducing healthcare disparities in cardiovascular disease and stroke. She also focuses on quality improvement program design, implementation and evaluation research, and research on provider behavior. Some of her research is examining cognitive outcomes after stroke, seeking to understand the predictors and long-term trajectory of cognitive decline after stroke.

  • Mind Matters Newsletter

    The Center’s Outreach, Recruitment and Education team publishes a bi-annual newsletter, Mind Matters. It highlights recent activities, currently recruiting research studies, wellness programs, and education/outreach events. The newsletter also spotlights staff members, as well as the personal stories of our research or wellness participants.










  • Thank you for your interest in hearing from us!

    The Michigan Alzheimer’s Disease Center distributes several monthly e-newsletters. Please take a look at the options below, and consider subscribing to those in which you are interested. Each is distributed monthly, and you may unsubscribe at any time.

    If you have any additional questions, you can contact us at 734-936-8803.

  • This section shares disease information and printable flyers compiled by our Center’s experts.

    Mild cognitive impairment

    What is mild cognitive impairment?
    Mild Cognitive Impairment (MCI) is a disorder of memory or other related cognitive process. A person with MCI experiences greater memory and thinking difficulties than expected with aging. However, the problems do not impair their ability to complete daily activities (as they do in other diseases causing dementia). It is important to recognize MCI because it puts a person at a greater risk of developing dementia in the future. For a one page informational flyer on MCI, click here.

    What are the causes of mild cognitive impairment?
    The causes of MCI are not yet completely understood. Experts believe that many cases – but not all – result from brain changes occurring in the very early stages of Alzheimer’s disease or other dementias.

    What are the symptoms of mild cognitive impairment?
    Experts classify MCI based on the thinking skills affected:

    Amnestic MCI
    Amnestic MCI primarily affects memory. A person with Amnestic MCI may
    start to forget important information that they would have previously recalled
    easily, such as:

    • Appointments
    • Conversations
    • Recent events

    Nonamnestic MCI
    Nonamnestic MCI affects thinking skills other than memory. Thinking skills that may be affected by nonamnestic MCI include:

    • Making sound decisions
    • Judging the time or sequence of steps needed to complete a complex task
    • Visual perception

    How is mild cognitive impairment diagnosed?
    MCI is a clinical diagnosis representing a doctor’s best professional judgment about the reason for a person’s symptoms. If a physician has difficulty confirming a diagnosis of MCI or the cause of MCI, brain imaging and
    cerebrospinal fluid tests may be performed to determine if the individual has MCI due to Alzheimer’s disease.

    A medical exam for MCI includes:

    • Thorough medical history
    • Assessment of independent function and daily activities
    • Input from a family member on function
    • Assessment of mental status
    • In-office neurological exam
    • Evaluation of mood
    • Laboratory tests

    What are the prognosis and options for treatment?
    There aren’t currently medications to slow the decline that can occur with MCI. Drugs approved to treat symptoms of Alzheimer’s disease may help those with MCI, but have not been shown to prevent progression of MCI to dementia.

    Some studies suggest that the following may help slow decline:

    • A healthy diet
    • Exercise
    • Participation in mentally simulating and socially engaging activities

    Where can I learn more?
    More information about mild cognitive impairment can be found at:

    • A one page infographic created by our Center's experts is available for download here. 
    • The Alzheimer’s Association: www.alz.org or by calling (800) 272-3900
    • The National Institute on Aging: www.nia.nih.gov or by calling (800) 438-4380
    Alzheimer's Disease

    What is Alzheimer’s disease?
    Alzheimer’s disease (AD) is a brain disease that causes damage to and destruction of nerve cells. It is the most common cause of dementia, which is a decline in thinking that interferes with one’s everyday functions. For a one page informational flyer on AD, click here.

    A person with AD has difficulty:

    • Remembering
    • Solving problems
    • Communicating

    A person with AD may also have changes in:

    • Personality
    • Mood
    • Behavior

    AD slowly worsens over time. It is believed that more than 5 million Americans over the age of 65 and at least 200,000 people in America under the age of 65 have the disease.

    What are the causes of Alzheimer’s disease?
    In AD, the brain contains abnormal protein deposits that form plaques (beta amyloid protein) and tangles (tau protein) around and within nerve cells. The abnormal proteins interfere with the normal function of nerve cells and eventually result in nerve cell death. We now know that the changes in the brain that cause AD begin at least 20 years before a person develops symptoms of the disease. There is no known single cause of AD. However, scientists have learned a great deal about what factors may increase a person’s risk of developing AD. The single most important risk factor for developing AD is getting older. The likelihood of developing AD doubles every 5 years after age 65.

    Additional factors that influence the risk of developing AD include:

    • Family history
    • Certain genes
    • Other health conditions such as diabetes
    • Diet
    • Exercise practices
    • Education

    What are the symptoms of Alzheimer’s disease?

    AD is often described in “stages”. Different symptoms mark the different
    stages of AD, though this varies from person to person. Progression from stage
    to stage is gradual.

    Early stage
    AD begins gradually and may, at first, be difficult to recognize. Commonly described difficulties include trouble with the following tasks:

    • Remembering recent events
    • Keeping track of time
    • Naming familiar people or things
    • Solving problems
    • Planning
    • Learning new things

    Middle stage
    Memory loss progresses and people find it more difficult to:

    • Read
    • Write
    • Speak
    • Perform household tasks
    • Choose clothing
    • Bathe without reminders

    Late stage
    A person with advanced AD is often unable to:

    • Communicate
    • Recognize people, places, or objects
    • Walk

    They may sleep most of the time and often need full-time care.

    How is Alzheimer’s disease diagnosed?
    No single test leads to a diagnosis of AD. Rather, a diagnosis is made after a complete evaluation that includes:

    • A detailed history and physical exam, including information from family members or others who the person spends a lot of time with
    • Tests to evaluate memory and thinking
    • Blood tests, brain scans, and in some cases spinal fluid testing

    What are the prognosis and options for treatment?
    There is no known cure for AD. The duration of the disease can vary from a few years to more than 20, though most people with the disease die approximately 8-10 years after being diagnosed.

    There are five different prescription drugs used to treat AD:

    • Donepezil (Aricept®)
    • Galantamine (Razadyne®)
    • Rivastigmine (Exelon®)
    • Memantine (Namenda®)
    • A combination drug called Namzaric®

    Where can I learn more?
    More information about AD can be found at:

    • A one page infographic created by our Center's experts is available for download here.
    • A one page infographic breaking down the difference between Alzheimer's disease and dementia is available for download here.
    • A one page infographic detailing Alzheimer's disease genetics is available for download here.
    • The Alzheimer’s Association: www.alz.org or by calling (800) 272-3900
    • The National Institute on Aging: www.nia.nih.gov or by calling (800) 438-4380
    Lewy body disease

    What is Lewy body dementia?
    Lewy body dementia (LBD) is a brain disease that impairs thinking and often mobility. It is the third most common cause of dementia after Alzheimer’s disease (AD) and vascular dementia. LBD accounts for up to 20% of all dementia cases in the United States. For a one page informational flyer on LBD, click here.

    What are the causes of Lewy body dementia?
    The cause of LBD is not known and it is rarely inherited. In LBD, the brain contains abnormal protein deposits known as Lewy bodies. Lewy bodies also occur in Parkinson’s disease (PD), but are less widespread. In addition to Lewy bodies throughout the brain, the microscopic brain abnormalities found in AD are often also present with LBD.

    What are the symptoms of Lewy body dementia?
    A person with LBD may experience:

    • Cognitive difficulties
    • Visual hallucinations
    • Significant day-to-day fluctuations in abilities
    • Stiffness and slowness of movement
    • Tremors
    • Poor balance and falls
    • Fainting or other periods of unresponsiveness
    • Acting out dreams

    How is Lewy body dementia diagnosed?
    LBD is often confused with AD or PD. Accurate diagnosis is critical because people with LBD have distinct symptoms that require different treatment strategies and may be sensitive to certain medications.

    A diagnosis of LBD is made after a thorough evaluation, which includes:

    • A discussion of symptoms
    • A physical exam
    • Diagnostic testing

    Blood tests and brain scans are often performed. The diagnosis may be confirmed after death with a brain autopsy showing Lewy bodies.

    What are the prognosis and options for treatment?
    LBD worsens over time and impairs the individual’s ability to live and function independently. Though there is not a known cure for LBD, three types of medications may be used to treat it.

    • Cholinesterase inhibitors such as Aricept®, Razadyne, or Exelon®
    • Drugs used to treat people with PD such as Sinamet®
    • Drugs for visual hallucinations and behavioral problems

    Where can I learn more?
    More information about Lewy Body dementia can be found at:

    • A one-page infographic created by our Center's experts is available for download here.
    • The Alzheimer’s Association: www.alz.org or by calling (800) 272-3900
    • The National Institute on Aging: www.nia.nih.gov or by calling (800) 438-4380
    Vascular dementia

    What is vascular dementia?
    Vascular dementia is a decline in thinking skills caused by conditions that block or reduce blood flow to various regions of the brain, depriving them of oxygen and nutrients. Vascular dementia is considered the second most common cause of dementia after Alzheimer’s disease, accounting for up to 30% of cases. For a one page informational flyer on vascular dementia, click here.

    What are the causes of vascular dementia?
    Any condition that damages blood vessels anywhere in the body can cause brain changes linked to vascular dementia. Advancing age is a major risk factor.

    Additional risk factors are the same ones that raise risk for heart problems, stroke, and other diseases that affect blood vessels. Follow these steps to reduce the risk of developing vascular dementia:

    • Don’t smoke
    • Keep a healthy blood pressure, cholesterol level, and blood sugar
    • Eat a healthy diet
    • Exercise
    • Maintain a healthy weight
    • Limit alcohol consumption

    What are the symptoms of vascular dementia?
    A person with vascular dementia may experience:

    • Confusion
    • Trouble paying attention and concentrating
    • Reduced ability to organize thoughts
    • Problems with memory
    • Restlessness and agitation
    • Depression

    How is vascular dementia diagnosed?
    Sometimes vascular dementia is difficult to distinguish from Alzheimer’s disease. In many cases, a person may have both vascular dementia and Alzheimer’s disease. This is referred to as mixed dementia or Alzheimer’s
    disease with stroke (or mini-strokes).

    What are the prognosis and options for treatment?
    Unfortunately, there are no treatments that can reverse the damage that has been done to the brain after it has occurred. However, physical therapy can help people recover immediately after a stroke. Medications and lifestyle changes can help prevent additional strokes.

    Medications used to treat Alzheimer’s disease may also be helpful with vascular dementia.

    Where can I learn more?
    More information about vascular dementia can be found at:

    • A one page infographic created by our Center's experts is available for download here.
    • The Alzheimer’s Association: www.alz.org or by calling (800) 272-3900
    • The National Institute on Aging: www.nia.nih.gov or by calling (800) 438-4380
    Frontotemporal dementia

    What is frontotemporal dementia?
    Frontotemporal dementia (FTD) refers to a group of diseases that damage the frontal or temporal lobes of the brain, resulting in significant changes in personality, behavior, and language ability. As a result, it is often misdiagnosed as a psychiatric disorder. For a one page informational flyer on FTD, click here.

    The majority of people diagnosed with FTD are between the ages of 40 and 65.

    Examples of FTD include:

    • Pick’s disease
    • Frontotemporal dementia with motor neuron disease
    • Primary progressive aphasia
    • Corticobasal degeneration

    FTD accounts for only about 5% of all dementia cases in the United States, but is one of the most common types of dementia in younger individuals.

    What are the causes of frontotemporal dementia?
    The cause of FTD is not known, and may differ between individuals. In about half of FTD patients, a normal brain protein called tau accumulates abnormally and forms deposits. In others, a separate protein known as TDP43 accumulates in the same way.

    Unlike other dementias, FTD is highly heritable. Approximately 40% of individuals with FTD have an affected family member. In these individuals, FTD is usually caused by changes in one of their genes.

    The diagnosis may be confirmed after death with a brain autopsy. Genetic testing can help reveal an underlying mutation responsible for FTD in about 40% of patients.

    What are the symptoms of frontotemporal dementia?
    FTD usually begins with gradual changes in personality, behavior, or speech. People with FTD may also have motor difficulties similar to those with Parkinson’s disease (rigidity and slowness of movement), or amyotrophic lateral sclerosis (weakness). Memory loss is present in FTD, but less obvious than in other types of dementia.

    Other symptoms can include:

    • Decreased speech
    • Inability to name common objects
    • Loss of motivation
    • Lack of concern or sympathy for others
    • Inappropriate social or sexual behavior
    • Rigid, inflexible thinking
    • Compulsive, repetitive behaviors

    How is frontotemporal dementia diagnosed?
    An accurate diagnosis is important and should be made after the following have been done:

    • A thorough discussion of symptoms with a doctor
    • A careful medical history
    • Examination of changes in behavior
    • A physical exam
    • Other tests

    Blood tests and brain scans are often performed. MRI or CT scans may show abnormalities in the frontal or temporal lobes of the brain. PET or SPECT scans may be helpful in distinguishing FTD from other causes of dementia.

    What are the prognosis and options for treatment?
    FTD worsens over time and impairs the individual’s ability to live and function independently. Although there is no cure for FTD, there are medications that can help control the behavioral symptoms of the disorder. With an accurate diagnosis, unnecessary medications can be removed that might otherwise worsen the disease symptoms.

    Where can I learn more?
    More information about frontotemporal dementia can be found at:

    • A one page infographic from our Center's experts is available for download here.
    • The Alzheimer’s Association: www.alz.org or by calling (800) 272-3900
    • The National Institute on Aging: www.nia.nih.gov or by calling (800) 438-4380
    Primary progressive aphasia

    A one page infographic created by our Center's experts is available for download here.

    This section shares information on Alzheimer’s caregiving topics created by the National Institute on Aging.

    Caring for Yourself

    Taking care of yourself is one of the most important things you can do as a caregiver. This could mean asking family members or friends to help out, doing things you enjoy, using adult day care services, or getting help from a local home health care agency. Taking these actions can bring you some relief. It also may help keep you from getting ill or depressed. Find the resource here. 

    Managing Personality & Behavior Changes

    Alzheimer’s disease causes brain cells to die, so the brain works less well over time. This changes how a person acts. This tip sheet has suggestions that may help you understand and cope with changes in personality and behavior in a person with Alzheimer’s disease. Find the resource here.


    Many people with Alzheimer’s disease wander away from their home or caregiver. As the caregiver, you need to know how to limit wandering and prevent the person from becoming lost. This will help keep the person safe and give you greater peace of mind. Find the resource here.


    At some point, people with Alzheimer’s disease will need help bathing. Because this is a private activity, people may not want help. They may also feel angry about not being able to take care of themselves.

    Helping someone with Alzheimer’s disease take a bath or shower can be one of the hardest things you do. Planning can help make bath time better for both of you. If the person is afraid of bathing, follow his or her lifelong bathing habits, such as doing the bath or shower in the morning or before going to bed. Find the resource here.

    This section shares local resources for older adults living with or caring for someone with dementia.

    Alzheimer's Association - Greater Michigan Chapter

    The Alzheimer's Association - Greater Michigan Chapter is based in Southfield and serves the entire state. They offer Alzheimer's disease support groups and educational programs in many Michigan counties. Visit their site here for details specific to your area.

    Financial Trainings & Tips for Caregivers - Older Adult Nest Egg, Wayne State University 

    Worried that your parents are beginning to decline cognitively? While many programs for caregivers are designed to address the emotional, physical and mental needs of the older person and the caregiver, one critical aspect of caregiving is overlooked: Financial health. Older Adult Nest Egg (OANE) developed a friends/family component designed to help caregivers maintain the financial health of an older loved one. How can you talk with the older person about financial management and/or protecting her finances? How do you discover if your older loved one is the victim of scams or identity theft? Do you know the dos and don’ts of managing your older loved one’s finances while protecting your own? Online, narrated trainings are now available at no cost. Developed under the leadership of Dr. Peter Lichtenberg at the Wayne State University Institute of Gerontology, trainings can be accessed here. In addition to the online training there are resources and news alerts. A do it yourself assessment to determine how vulnerable your older love one may be to exploitation will soon be available. Financial health is caregiving health. Visit olderadultnestegg.com. 

    Successful Aging thru Financial Empowerment - Wayne State University

    Successful Aging thru Financial Empowerment (SAFE) provides FREE financial coaching to older adults and caregivers to manage money securely and accurately. Contact Program Director LaToya Hall to talk by phone or email: l.hall@wayne.edu or 313-664-2608. Assistance is safe, confidential and free. The SAFE website is available here for more information. 

    Area Agency on Aging 1B

    The AAA-1B provides information on senior services, assistance, resources, and home care in southeast Michigan. Visit their site here.

    AARP Michigan

    AARP Michigan offers a dementia resource guide for seniors. Please find it here. 

    This section shares national resources for older adults living with or caring for someone with dementia.

    Alzheimer’s Disease Education and Referral Center (ADEAR) by the National Institute of Aging

    The Alzheimer’s Disease Education and Referral Center (ADEAR) by the National Institute of Aging provides current, comprehensive information and resources on Alzheimer’s disease and related disorders. Find the site here.

    A great brain health flyer from the NIA is available here.

    Alzheimer's Research Forum

    The Alzheimer’s Research Forum provides updates on published research findings, topical news group discussions, and online chats. Click here for the site.

    Alzheimer's Association

    The national chapter of the Alzheimer's Association offers many disease and caregiver resources, as well as a 24/7 helpline. Visit the national site here.

    A great brochure by the Association titled "Partnering with your Doctor: A Guide for Persons with Memory Problems and their Care Partners" is available here.

    Lewy Body Dementia Association

    The Lewy Body Dementia Association provides information, resources, and support groups for people living with Lewy body dementia here.

    Aging with Dignity

    Aging with Dignity - Provides information on the Five Wishes document, an end-of-life care planning document for families and organizations.

    This section shares our staff’s top book recommendations for the dementia journey.